COLLEGIUM PHARMACEUTICAL, INC
For the period ended May 12, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
May 12, 2026 · Filed May 12, 2026
Use the contents to explore the available documents and sections.
COLL$24.21-3.8%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Strategic Rationale
Strategic Rationale
| · | Strategically aligns with Collegium’s mission of building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions by expanding its position in ADHD and further diversifying its commercial portfolio beyond responsible pain management. |
| · | Leverages Collegium’s established ADHD commercial infrastructure and expertise to accelerate AZSTARYS’ growth trajectory and drive operational efficiencies, further strengthening Collegium’s financial position. Annual run rate synergies expected to be in excess of $50 million within twelve months. |
| · | Strengthens Collegium’s position in ADHD. AZSTARYS generated more than 760,000 prescriptions in 2025 and adds a complementary medicine to Collegium’s ADHD portfolio. AZSTARYS is expected to generate $60 to $70 million of net revenue during the remainder of 2026. |
| · | Expected to extend the longevity of Collegium’s revenue base as AZSTARYS is supported by six Orange Book-listed patents, most of which do not expire until December 2037. |
| · | Further strengthens Collegium’s financial position by increasing revenues, supporting margin expansion, and enhancing future cash flow generation. |
For additional background on the acquisition, please read the announcement press release here and view Collegium’s investor presentation here.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.